Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome) by unknown
RESEARCH Open Access
Actigraphic investigation of circadian
rhythm functioning and activity levels in
children with mucopolysaccharidosis type
III (Sanfilippo syndrome)
Rachel A. Mumford1, Louise V. Mahon2, Simon Jones4, Brian Bigger5, Maria Canal6 and Dougal Julian Hare3*
Abstract
Background: Sleep disturbance is part of the behavioural phenotype of the rare genetic condition mucopolysaccharidosis
(MPS) type III. A growing body of evidence suggests that underlying disturbance in circadian rhythm functioning
may explain sleep problems within the MPS III population.
Methods: Actigraphic data were recorded in eight children with MPS III over 7–10 days and compared to
age-matched typically developing controls. Parameters of circadian rhythmicity and activity levels across a 24-h period
were analysed.
Results: Statistically and clinically significant differences between the two groups were noted. Analysis indicated that
children with MPS III showed significantly increased fragmentation of circadian rhythm and reduced stability with
external cues (zeitgebers), compared to controls. Average times of activity onset and offset were indicative of a phase
delayed sleep-wake cycle for some children in the MPS III group. Children with MPS III had significantly higher activity
levels during the early morning hours (midnight–6 am) compared to controls.
Conclusions: Results are consistent with previous research into MPS III and suggest that there is an impairment in
circadian rhythm functioning in children with this condition. Implications for clinical practice and the management of
sleep difficulties are discussed.
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Background
Sleep and circadian rhythm functioning in intellectual and
developmental disability
There is evidence that sleep disturbance and disorder
occur more frequently in the intellectual and develop-
mental disability (IDD) population [1, 2]. Prevalence es-
timates have been reported as high as 85 % [3, 4]
although rates vary with age, level of disability and par-
ental perceptions of sleep problems. Settling difficulties
(increased sleep latency), frequent night waking, para-
somnias, co-sleeping and daytime sleepiness are the
most common difficulties described by parents [5, 6].
There is evidence that deficient or disrupted sleep can
confer numerous disadvantages for the individual, in-
cluding adverse effects on cognition, physical health and
daytime behaviour [7, 8]. Poor parental psychological
wellbeing is also associated with sleep disturbance in
children with IDD [9, 10].
A number of explanations for this increased incidence
of sleep disruption within the IDD population exist,
including co-morbid physical health conditions, pain,
sensory differences and environmental factors [11, 12].
Alongside these factors, a growing body of research has
identified underlying circadian rhythm disruption as a
further explanation of sleep problems in IDD. Circadian
rhythms are internally generated physiological and
behavioural cycles that occur across a 24-h period. They
are influenced by internal biological factors and ex-
ternal environmental cues (zeitgebers) and include
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the sleep-wake cycle, hormone production and core
body temperature regulation. Disturbance in circa-
dian rhythm functioning has been reported in chil-
dren and adults with autistic spectrum disorders [13–16],
Smith-Magenis syndrome [17], Rett syndrome [18] and
Angelman syndrome [19], amongst other IDD conditions.
Specific circadian rhythm differences highlighted have in-
cluded both phase advanced and delayed sleep syndrome,
irregular sleep-wake patterns, increased fragmentation of
rhythmicity and reduced stability or association with ex-
ternal zeitgebers.
Endogenous melatonin plays a role in the regulation
of several bodily rhythms, including the sleep-wake cycle.
Consequently, consistent with reports of sleep disturbance,
abnormalities in levels of melatonin or in melatonin pro-
duction have been identified in autism [20], Angelman syn-
drome [19] and Smith-Magenis syndrome [21]. Specifically
in Smith-Magenis syndrome, a complete inversion of the
circadian rhythm of melatonin release has been described
and connected to the sleep disturbance and daytime behav-
ioural difficulties observed in this condition [17, 21]. Ac-
cordingly, exogenous melatonin is often used as treatment
for sleep disturbance for individuals with IDD [22, 23]
although the potential value of behavioural sleep hygiene
interventions is not dismissed [7].
Sleep in MPS III
The mucopolysaccharide (MPS) disorders comprise a
group of inherited metabolic diseases in which specific
lysosomal enzymes are absent or deficient, causing cellu-
lar accumulation of glycosaminoglycans (GAGs). This
accumulation impairs cellular function across organs
[24, 25]. MPS III (Sanfilippo syndrome) is characterised
by a deficiency in one of four enzymes involved in the
metabolism of the glycosaminoglycan heparin sulphate.
There are four corresponding subtypes (MPS III A, B, C
and D) based on the specific enzyme alteration [26].
MPS III is the most common of the MPS disorders, with
incidence estimated at 1 in 20, 000 live births [24]. It is
characterised by a clinical course of three phases, involv-
ing progressive cognitive and physical deterioration [24,
26]. In the first phase (1–4 years), developmental delay
becomes increasingly apparent after an initial period of
typical development. The second phase begins between
3 to 4 years and is marked by an increasing loss of func-
tion, severe sleep disturbance and behavioural difficul-
ties, including hyperactivity and aggression. The third
phase (10+ years) is characterised by progressive loss of
skills, increased motor difficulties, seizures and respira-
tory complications. Life span is significantly reduced,
with death often reported in the second or third decade
[26]. Current clinical treatment focuses on symptom
management although potential therapies that will at-
tempt to modify the progression of the disease (enzyme
replacement therapy, gene therapy and haematopoietic
stem cell transplantation) are under development [27].
Sleep disturbance has consistently been reported in
MPS III, with incidence rates of 87–92 % [28–31] and is
therefore described as part of the behavioural phenotype
of the condition [32]. Parent report studies have identi-
fied a broad spectrum of sleep difficulties, including dif-
ficulty initiating sleep, frequent night/early morning
waking, disruptive behaviour at night (e.g. wandering,
singing) and daytime sleepiness [28, 29, 31, 33]. Clini-
cians working with families affected by MPS III also
report these as the main presenting sleep-related diffi-
culties [34]. Objective measurement of sleep in MPS III
has been carried out in two studies. Actigraphic analysis
undertaken with eight individuals with MPS III subtype
A or B revealed significantly longer sleep onset latencies
and increased daytime sleep in the MPS III group com-
pared to controls [33]. There were also trends towards
increased night waking and reduced sleep efficiency in
the MPS III group. Older age was associated with longer
sleep onset latency and diminished sleep efficiency for
individuals with MPS III. Parent questionnaire responses
indicated significantly greater sleep disturbance across
all domains in the patient group compared to controls.
One study [35] has used polysomnography (PSG) and
electroencephalogram (EEG) to investigate sleep in a
small sample of individuals aged 7–20 years with MPS
III subtype A. Compared to controls, there was reduced
nocturnal sleep duration, REM sleep and slow wave
sleep, alongside greater daytime sleep in the MPS III
group. Older individuals with MPS III were reported to
show an irregular and fragmented sleep-wake pattern,
with no identifiable circadian rhythm.
There is growing evidence that sleep disturbance in
MPS III may be explained by an abnormality in the diur-
nal release of melatonin. Levels of melatonin production
in MPS III have been shown to be significantly lower at
night and higher during the day [36]. Additionally,
Mahon et al. [33] reported no significant variation in
melatonin concentration across three time points within
a 24-h period in MPS III patients. This suggests an alter-
ation in circadian melatonin production, given that
levels can be differentiated across time in typically devel-
oping children. These findings directly correspond with
subjective and objective reports of the nature of sleep
disturbance observed in MPS III (i.e. difficulty initiating
sleep at night, night waking and daytime sleepiness) and
parallel research into sleep disturbance and an inversion
of the circadian rhythm of melatonin release observed in
Smith-Magenis syndrome [17, 21]. Alterations in circa-
dian functioning have also been demonstrated in murine
models of MPS III [37, 38], with MPS IIIB mice showing
weaker circadian rhythm cycles, increased activity levels
during rest phases and a marked late peak of activity
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within the light/dark cycle compared to age-matched
control mice.
There is limited research into treatment for sleep dis-
turbance in MPS III. Given the abnormalities in diurnal
melatonin concentration, exogenous melatonin is often
the pharmacological treatment of choice, with some
level of effectiveness reported by parents in approxi-
mately 70 % of individuals with MPS III [31]. In this
study [31], 60 % of families also reported some degree of
success with behavioural strategies although only 37 %
of the overall sample had tried a behavioural interven-
tion. There is therefore undoubtedly scope for further
research into the acceptability and effectiveness of be-
havioural intervention for sleep in MPS III. Finding ef-
fective treatment is critical given that sleep disturbance
has a major impact on individuals with MPS III and
their families. Parents report disrupted sleep patterns for
the whole family [29], and both parents and clinicians
have described associations between sleep difficulties
and increased daytime challenging behaviour in children
with MPS III [31,34]. Sleep disturbance places extra
strain on parents who are already coming to terms with
their child’s diagnosis and its emotional, social and fi-
nancial burdens. Previous research has indicated that
parents of children with MPS III experience clinically
significant levels of depression and anxiety [39, 40].
There are, therefore, significant clinical implications for
families if an increased understanding of sleep and circa-
dian rhythmicity in MPS III results in tailored, effective
interventions.
Aims and hypotheses
This study formed part of a wider investigation into
MPS III undertaken at the University of Manchester in
conjunction with the Department of Genetic Medicine,
St Mary’s Hospital, Manchester. This paper presents
additional analysis of the data published by Mahon et al.
[33]. The primary aim was to specifically examine pa-
rameters of circadian rhythm functioning related to the
activity/rest cycle in children with MPS III through the use
of objective actigraphic assessment. It was hypothesised
that children with MPS III would exhibit a significantly
different pattern of circadian functioning, compared to
typically developing (TD) controls.
Methods
The National Research Ethics Service North West-
Lancaster Research Ethics Committee approved the
research protocol.
Participants
Ten families of children with MPS III expressed an
interest in participating; however, two families were sub-
sequently withdrawn from the study due to technical
problems with actigraphic recording and one child’s add-
itional health complications. Consequently, eight chil-
dren with MPS III took part in the study: five males and
three females, aged 2–15 years (mean = 9 years 3 months,
SD = 4.86). Individual demographic information is pre-
sented in Table 1. All children had a diagnosis of MPS
III subtype A or B. Diagnosis was verified through urine/
specific-enzyme analysis, and the presence of sleep dis-
turbance was not a prerequisite to participation. Exclu-
sion criteria were as follows: (i) concurrent involvement
in an enzyme replacement study, (ii) previous bone
marrow transplant, (iii) serious disease affecting another
organ, or (iv) child considered near the end of life. The
two eldest children with MPS III subtype A had epilepsy.
Older children were prescribed more medications, in-
cluding medication for sleep (melatonin, chloral hydrate,
Table 1 Demographic information of MPS III participants




MPS1 Male 2 B Pakistani None None
MPS2 Male 4 A White Polish None None
MPS3 Male 5 B White British None Behavioural advice (parents
had already tried techniques)
MPS4 Male 10 B Pakistani Melatoninb (good for settling) Loperamide Herbal medicine (no effect
after first week)
MPS5 Female 10 B Pakistani Walking (helpful)Risperidone (no effect) None
MPS6 Female 11 A White British Gonapeptyl None
MPS7 Male 14 A White British Chloral hydrate, zopiclone (short-term effects
only), levetiracetam, ibuprofen, hyoscine
Melatonin (short-term effect only)
Behavioural techniques (no effect)
MPS8 Female 15 A White British Zopiclone, clonazepam, midazolam, sodium
valproate, Senokot, Movicol, omeprazole,
glycopyrrolate, morphine, paracetamol
Melatonin (no effect) Temazepam
(initial effect but discontinued
due to distress/tearfulness)
aEffectiveness of intervention for sleep as reported by parents
bMelatonin treatment ceased 2 weeks prior to data collection
Mumford et al. Journal of Neurodevelopmental Disorders  (2015) 7:31 Page 3 of 11
zopiclone). Given the established effect of exogenous
melatonin on circadian rhythmicity [41], this treatment
was discontinued 2 weeks prior to data collection. All
other medication was unchanged throughout data col-
lection. Previous interventions for sleep had been
attempted for four children with MPS III (including
melatonin, herbal medication and behavioural tech-
niques) with limited effectiveness as reported by par-
ents. Eight children, four males and four females,
aged 3–15 years (mean = 8 years 7 months, SD = 4.85)
formed an age-matched (within 1 year), TD control
group. These children were not taking any medication
and did not have developmental disability, neurological
disorder, brain injury, sleep disorder or mental health
difficulties.
Procedure
All eligible families of a child with MPS III under the
care of St Mary’s Hospital, Manchester, or registered
with the MPS Society UK were sent a recruitment letter
providing brief details of the project and asking them to
make initial contact with the researchers. The control
group was comprised of children of colleagues from the
University of Manchester or local NHS Trust. Interested
families were given participant information sheets, and a
home visit was subsequently conducted to obtain con-
sent, explain actigraphy and collect demographic data.
Written informed consent was obtained from a parent
of each child. In the TD control group, participants aged
14 to 15 years gave their informed consent and assent
was also obtained from those aged 6 to 13 years. Partici-
pants received a gift voucher for taking part.
Actigraphy
Actigraphy allows for the collection of naturalistic data
over an extended time period and has been shown to
correlate highly with PSG [42]. Either a Cambridge
Neurotechnology AW4 or Respironics Actiwatch 2 acti-
graph was used to obtain data. These are equivalent
models of actigraph produced under different names
allowing for comparability of data. All children wore the
actigraph on their non-dominant wrist continuously for
7–10 days as recommended by previous research [43].
Actigraphs were only removed when washing or swim-
ming. Data was sampled across 15-s epochs. To ensure
comparability of data across subjects and to limit any
seasonal impact on circadian functioning, all data was
collected during a standard school week within a 6-month
period.
Circadian rhythm and activity parameters
Actigraph data was downloaded and analysed using
Actiware version 5.5 to provide the following established
non-parametric indices of rhythmicity [44]:
i. L5 and M10 onset specify the average time of the
start of the least active 5-h period (L5) and the most
active 10-h period (M10) across a circadian cycle
and provide an indication of the extent to which an
individual’s circadian cycle is coordinated with a normal
24-h cycle.
ii. Relative amplitude is derived from the normalised
difference between the most active 10-h period and
least active 5-h period in an average 24-h pattern
and indicates the quantity of activity, with a range of
0–1 (higher values represent a greater divergence
between most and least active phases).
iii. Intra-daily variability indicates fragmentation of an
individual’s rhythm, through assessing the frequency
and extent of transitions between rest and activity,
and is derived as a ratio of the mean squares of the
differences between all successive hours and the
mean squares of difference within the grand mean.
Derived scores range from 0–2, with higher values
indicative of increased fragmentation.
iv. Inter-daily stability specifies the invariability of 24-h
rhythm between days and is the 24-h value from a
chi-square periodogram, normalised for number of
data points. It provides an indication of the strength
of the linkage of the circadian rhythm to external
zeitgebers that are deemed to be stable within the
period of recording (e.g. daylight), with a range of
0–1 (higher values indicate greater stability). The
parameter is derived by examining the regularity
of the pattern of data points across each day of
recording.
v. Periodicity specifies the time of the peak correlation
of the ‘best fit’ of any given rhythm within the
parameters of the expected circadian cycle of
24 h ± 15 min.
In addition, overall levels of activity were measured
across each of the four quadrants of a 24-h period (i.e.
midnight–6 am, 6 am–12 pm, 12 pm–6 pm and 6 pm–
midnight). This data allowed for analysis between groups
of potential differences in activity at particular time
points during the day. Total activity counts were also
generated for each day and averaged across the record-
ing period.
Statistical analysis
SPSS version 20 was utilised for further analysis of
actigraphic data using non-parametric statistics (Mann-
Whitney U, Spearman’s Rank correlation). Two-tailed
tests were adopted throughout, with a significance level of
0.05. It was necessary to exclude actigraph data from one
night for several participants due to illness or non-
compliance; however, there was a minimum of seven
nights’ data for all participants.
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Results
Circadian rhythm analysis
Non-parametric circadian rhythm analysis [44] was per-
formed on the actigraph data obtained from all partici-
pants. Data was averaged over the recording period, as
indicated by previous research. Table 2 presents descrip-
tive statistics of circadian rhythm parameters for the
MPS III and control groups, alongside inferential ana-
lyses. As can be seen, mean intra-daily variability was
significantly greater in the MPS III group compared to
controls (U = 6.5, z = −2.68, p = 0.007, r = 0.67 (large
effect)), indicating increased fragmentation of rhythm
across the recording period. Additionally, mean inter-daily
stability was significantly lower in the MPS III group than
in the control group (U = 13.0, z = −1.99, p = 0.046, r = 0.5
(large effect)), showing less stability of rhythm across days
in relation to external zeitgebers. Despite lower mean
relative amplitude in the MPS III group, this was not
found to be significantly different to controls (U = 16.0,
z = −1.68, p = 0.093, r = 0.42 (medium-large effect)).
Mean periodicity (peak correlation of circadian rhythm)
did not differ between groups (U = 29.5, z = −0.27, p =
0.785, r = 0.06), but the standard deviation for period-
icity was much greater in the MPS III group, with some
children showing either a slightly phase advanced or de-
layed circadian rhythm cycle (see Fig. 1). Further analysis
via calculation of z-scores indicated that half of the MPS
III group demonstrated significantly different periodicity
scores to controls. Two children showed significantly phase
advanced circadian rhythms (23½ hours, z = −4.54 and
23¾ hours, z = −3.19), whereas two children demonstrated
significantly phase delayed circadian rhythms (24½ hours,
z = 2.18 for both children). Figure 2 presents individual
MPS III group periodicity z-scores compared to con-
trols. The wide variation within the MPS III group
accounts for the non-significance of mean periodicity
group comparisons.
The data for L5 onset (least active 5-h period) and
M10 onset (most active 10-h period) indicated wide vari-
ability in both phases within the MPS III group. There
was a bimodal L5 onset of 11 pm and 2 am in the MPS
III group (range = 9 pm to 3 am), compared to a mode
of 11 pm for L5 onset in the control group (range =
10 pm to 1 am). The mode for M10 onset was 12 pm in
the MPS III group (range = 8 am to 12 pm) and 9 am for
controls (range = 8 am to 12 pm). Taken together, these
modal figures illustrated a later onset of wakefulness and
activity for children with MPS III, combined with wider
variation in the onset of their least active period. For
three children with MPS III, these parameters were indi-
cative of phase delay in the sleep-wake cycle (L5 = 2 am,
M10 = 11 am; L5 = 3 am, M10 = 12 pm; and L5 = 2 am,
M10 = 12 pm).
Activity analysis
Activity levels were averaged over the recording period
for each quadrant of a 24-h period (midnight–6 am,
6 am–12 pm, 12 pm–6 pm and 6 pm–midnight). Indi-
vidual data for the MPS III group is presented in Table 3,
with group comparisons in Table 4. There was wide vari-
ation in activity levels amongst the children with MPS
III. Five out of eight children had higher activity counts
towards the end of the day in the fourth quadrant
(6 pm–midnight), compared with their level of activity
during the morning (6 am–12 pm). This is further sug-
gestive of a phase delayed sleep-wake cycle. The youn-
gest three children, and in particular those in the second
phase of the disorder (aged 4 and 5 years), displayed the
highest overall levels of activity. The three children with
MPS III who had the lowest overall activity levels, which
included the eldest two children (14 and 15 years),
showed the least discrepancy in level of activity across
the 24-h period. An attenuated trajectory of activity for
children with MPS III is evident, with little observable dif-
ference in activity levels between the second (6 am–12 pm)
and fourth (6 pm–12 pm) time quadrants.
Group comparisons (see Table 4) indicated a significantly
greater mean level of activity for children with MPS III
within the first time quadrant (midnight–6 am), compared
to controls (U = 11.0, z = −2.21, p = 0.027, r = 0.55 (large ef-
fect)). There were no statistically significant differences be-
tween groups in the mean activity scores for the third
quadrant (12 pm–6 pm; U = 20.0, z = −1.26, p = 0.208, r=
0.31 (medium effect)) or fourth quadrant (6 pm–midnight;
U = 30.0, z = −0.21, p = 0.834, r = 0.05). Although descrip-
tive analysis suggested that activity levels were lower in the
MPS III group compared to controls for the second time
quadrant (6 am–12 pm), this difference did not reach statis-
tical significance (U = 18.0, z = −1.47, p = 0.141, r= 0.38
(medium-large effect)). However, following removal of one
extreme score within the MPS III group, a statistically
Table 2 Comparison of circadian rhythm parameters for MPS III
and control groups
MPS III (n = 8) Controls (n = 8)
Mean Median Mean Median U p
(SD) (IQR) (SD) (IQR) (2 tailed)
Relative
amplitude
0.85 0.94 0.95 0.95 16.0 0.93
(0.19) (0.13) (0.02) (0.04)
Intra-daily
variability
0.88 0.86 0.71 0.73 6.5 0.007**
(0.12) (0.22) (0.08) (0.14)
Inter-daily
stability
0.50 0.50 0.62 0.62 13.0 0.046*
(0.12) (0.20) (0.08) (0.14)
Periodicitya 1446.25 1455 1448.75 1445 29.5 0.785
(18.85) (35) (7.44) (7.50)
a24-h time converted to minutes
*p < 0.05; **p < 0.01
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significant difference between groups was detected (U =
10.0, z = −2.08, p = 0.037, r = 0.52 (large effect)). There was
no significant difference between groups in mean total
activity scores across the recording period (U = 21.0,
z = −1.16, p = 0.248, r = 0.29 (small-medium effect)).
Spearman’s rank correlational analyses were conducted
for both circadian rhythm and activity parameters. Des-
pite some observable differences in activity parameters
across age in the MPS III group, age was not signifi-
cantly correlated with any variables in either the MPS III
Fig. 1 Periodicity (time of peak correlation) for MPS III and control group
Fig. 2 Periodicity z-scores for MPS III group compared to controls
Mumford et al. Journal of Neurodevelopmental Disorders  (2015) 7:31 Page 6 of 11
or control group. There was a trend towards a negative
relationship between age and relative amplitude in the
MPS III group (r = −0.70, p = 0.056) indicating, in line
with descriptive statistics, that older children had less
differentiation between the most and least active phases
across the 24-h period.
Discussion
As hypothesised, actigraphic assessment of circadian
rhythm and activity parameters revealed clinically and
statistically significant differences between children with
MPS III and TD controls. Children with MPS III dem-
onstrated significantly increased variability and fragmen-
tation of circadian rhythm (intra-daily variability) across
a 7–10-day period, with less stability of rhythm across
days in relation to external zeitgebers (reduced inter-
daily stability). There was a marginal trend towards
lower relative amplitude in the MPS III group, suggest-
ing that there was less differentiation between the most
and least active phases over the 24-h period compared
to TD controls. For children with MPS III, individual
periodicity scores and times of activity onset and offset
were indicative of incidences of both phase delayed and
phase advanced sleep-wake cycles although phase delay
was more common. There was also greater variability of
activity onset and offset times within the MPS III group,
which is consistent with results for intra-daily variability
and inter-daily stability parameters.
Descriptive analysis of activity level patterns showed a
shallower rhythm of activity in the MPS III group, which
was attenuated in its rise and fall. This finding corre-
sponds with a trend towards lower relative amplitude
(i.e. less differentiation between periods of activity and
rest) in individuals with MPS III. Children with MPS III
demonstrated significantly higher levels of activity in the
early morning hours (midnight–6 am) compared to con-
trols. Descriptive analysis suggested lower activity levels
between 6 am and 12 pm in the MPS III group and, after
the removal of one outlier, this difference was found to
be statistically significant. This is consistent with a later
onset of the most active 10-h period in the MPS III
group and provides evidence of a later onset of wakeful-
ness and activity, which is suggestive of phase delayed
circadian rhythm functioning.
Taken together, both circadian rhythm and activity pa-
rameters were indicative of disrupted circadian rhythm
Table 3 Activity levels in children with MPS III averaged over recording period
Participant ID (age)
Time quadrant MPS1 MPS2 MPS3 MPS4 MPS5 MPS6 MPS7 MPS8
(2) (4) (5) (10) (10) (11) (14) (15)
Midnight–6 am 9.33 6.59 6.47 2.72 7.87 4.25 7.08 27.14
6 am–12 pm 42.18 125.32 172.36 15.10 23.12 78.29 21.01 35.89
12 pm–6 pm 116.45 153.93 198.21 21.09 112.32 145.79 49.11 53.77
6 pm–Midnight 128.86 61.75 62.07 23.15 102.29 52.39 24.71 54.25
Total daily activity 296.82 347.59 439.11 62.05 245.61 280.72 101.92 171.05
Table 4 Comparison of activity levels for MPS III and control groups
MPS III (n = 8) Controls (n = 8)
Mean Median Mean Median U p
(SD) (IQR) (SD) (IQR) (2 tailed)
Midnight–6 am 8.93 6.84 3.79 4.03 11.0 0.027*
(7.64) (4.16) (2.12) (4.01)
6 am–12 pm 64.16 39.03 100.52 104.72 10.0 0.037*a
(57.17) (92.02) (23.38) (42.86)
12 pm–6 pm 106.33 114.39 142.99 158.19 20.0 0.208
(60.60) (101.62) (37.42) (66.59)
6 pm–Midnight 63.68 58.00 56.58 59.34 30.0 0.834
(36.10) (66.61) (19.31) (27.99)
Total daily activity 243.12 263.16 304.51 311.27 21.0 0.248
(126.23) (215.69) (55.38) (103.24)
aInferential analysis after removal of extreme outlier
*p < 0.05
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functioning in children with MPS III, and this may offer
some explanation of the significant sleep disturbance re-
ported within this population [28–31, 33]. Circadian
functioning was quantitatively different to TD controls
and this finding is consistent with previous research uti-
lising PSG, which reported irregular sleep-wake patterns
in individuals with MPS III [35]. With PSG methodology
some individuals with MPS III demonstrated no identifi-
able circadian rhythm of the sleep-wake cycle; however,
this finding was not replicated in the present study. This
inconsistency may be accounted for by the fact that the
PSG study also included adults with MPS III in their
sample, who would have been at a later stage of the
disease. An increased fragmentation of sleep and circa-
dian functioning has previously been associated with
older individuals with MPS III [33, 35]. Accordingly, in
the current study, there was a marginal trend towards
reduced differentiation between most and least active
phases and greater disruption in patterns of activity levels
in older children with MPS III. This provides further
tentative evidence that sleep and circadian rhythm dis-
turbance may be related to disease progression.
The finding that levels of activity were significantly
higher in the MPS III group in the early morning (mid-
night–6 am) extends previous reports of increased
nocturnal wakefulness in MPS III [35]. These bouts of
activity may likely relate to episodes of night behaviours
and parasomnias as reported by parents [31, 33].
Furthermore, the reduction in activity levels between the
hours of 6 am and 12 pm and a later onset of wakeful-
ness in the MPS III group may fit with parent and
clinician reports of daytime sleepiness [31, 34]. Both
these findings, along with non-parametric indices of
rhythmicity, are suggestive of phase delayed circadian
functioning in MPS III, although further investigation
with a larger sample is required to confirm this. Descrip-
tive analysis of activity data also demonstrated that
children in the second phase of MPS III (age 4 and
5 years) had the greatest levels of activity throughout the
day. This corresponds with clinical reports of hyperacti-
vity during this period [24, 26, 28].
Evidence of impairment in circadian rhythm function-
ing in MPS III is consistent with reports of an abnormal-
ity in endogenous melatonin concentrations [33, 36].
Melatonin secretion typically coincides with the onset of
darkness, peaks during the night and is inhibited in the
early morning with light onset. Paradoxically, melatonin
production in MPS III has been demonstrated to be sig-
nificantly lower at night and higher during the day [36]
corresponding with sleep onset difficulties and night
waking and daytime sleepiness, respectively. In the present
study, this could potentially offer an explanation for higher
activity levels between the hours of midnight–6 am and
reduced activity between 6 am–12 pm in children with
MPS III. An abnormality of melatonin production is also
consistent with significantly lower inter-daily stability
within the MPS III group, given the relationship between
melatonin secretion and external zeitgebers (e.g. light). As
a consequence, both lines of research point towards a po-
tential intrinsic alteration in circadian clock functioning in
MPS III, which is also consistent with murine models of
the condition [37]. The identification of circadian rhythm
disturbance in MPS III is also in line with previous re-
search into sleep and circadian functioning in various IDD
conditions [14–19]. Being ‘out of sync’ with environmen-
tal zeitgebers and the sleep-wake pattern of others is likely
to have a major impact on quality of life for the individual
and those who care for them. Learning opportunities or
valued activities may be hindered [7], and expressions of
challenging behaviour may be increased [3, 45], placing
further strain on family functioning. It is, therefore, of
central importance to address sleep-wake difficulties in in-
dividuals with MPS III.
Limitations
Given the rarity of MPS III, the sample size was small
and thus variability within the data may have limited
detection of statistically significant results. Accordingly,
some effect sizes for non-significant results were indicative
of difference between groups. There were observable clin-
ical differences in circadian rhythm functioning across age
(and consequently, disease stage) in the MPS III group,
with increased disruption in circadian rhythm generally in
older children. However, the small sample size limited the
statistical power to detect significant relationships based
on age/stage of disease and thus prevents any firm conclu-
sions from being drawn. It was also not possible to make
any comparisons between MPS III subtypes A and B,
which could be a critical factor given that subtype A is
considered more severe [46] and both the eldest children
were diagnosed with subtype A. The eldest two children
with MPS III also had epilepsy, which has been shown to
relate to sleep difficulties [47], but it was not possible to
investigate or control for the potential impact of this co-
morbid condition.
Although exogenous melatonin was withdrawn prior to
actigraphic monitoring, some children were prescribed
further hypnotic medications. It is possible, therefore, that
circadian rhythm parameters may have been further dis-
rupted for these children without medication use although
the effect may have only been minimal as there is evidence
that these medications have little effect on sleep architec-
ture [48]. More likely is the potential impact of these med-
ications on measurement of activity across the 24-h
period, based on a side effect profile of increased daytime
lethargy and somnolence [49]. This may partially explain
the overall lower levels of activity in the two eldest
children with MPS III taking these medications, although
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other circadian parameters were nonetheless indicative of
disrupted rhythmicity. Medication side effects is one of
the challenges posed by research into rare conditions [50],
and it may be particularly difficult to overcome in the
MPS III population, given the common co-morbidity of
physical health complaints.
Although some research has indicated that actigraphy
is less accurate in discriminating between sleep-wake
states in populations where sleep is fragmented [51], it
generally correlates highly with PSG data [42]. The re-
sults of the present study largely correspond with find-
ings obtained with PSG in an MPS III population [35].
Actigraphy has been used to differentiate sleep-wake
states in individuals with physical disabilities to an ac-
ceptable degree of reliability with PSG, albeit slightly
lower than for individuals without physical disability
[52]. Despite this, it may have been beneficial to include
measurement of any restrictions on physical activity in
the MPS III group (e.g. time spent in a wheelchair, use
of restraint), given that this is a common factor in MPS
III. There are further potentially relevant factors that
could have been recorded, including school attendance,
behavioural difficulties, parental management strategies
and family composition.
Future research
International, multi-centre research into circadian func-
tioning and sleep in MPS III would allow for validation
of the present findings in a larger sample and would en-
able comparisons between MPS III subtypes and across
stages of disease progression. It might also permit the
recruitment of unaffected siblings to act as a more ap-
propriate control group. Longitudinal analysis with acti-
graphy may also allow for exploration into potential
differences in ultradian rhythm functioning, which, given
the variability within the MPS III sample, may warrant
investigation. Simultaneous measurement of melatonin
and cortisol concentration levels across the 24-h period
would also enhance understanding of circadian clock
functioning and its relative contribution to sleep disturb-
ance within this population. There is evidence that in-
trinsic circadian clock functioning has an influence on
respiratory systems [53], and a high prevalence of sleep-
disordered breathing has been reported across all MPS
conditions [54]. Therefore, further work could usefully
examine whether there is a relationship between noctur-
nal breathing difficulties and circadian rhythm function-
ing in MPS III.
The relationship between sleep problems and day-
time challenging behaviour in IDD populations has
been identified in a number of studies [3, 5, 16, 45].
Given the high reported rates of behavioural difficul-
ties in MPS III [26, 39], combining actigraphy with
measurement of daytime behaviour would allow for
objective investigation of this potential relationship.
Additionally, further research may examine the rela-
tive contributions and effectiveness of behavioural
and pharmacological interventions for sleep problems
in MPS III.
Clinical implications
An increased understanding of circadian rhythm func-
tioning and sleep patterns of children with MPS III
has significant implications for individuals and fam-
ilies. ‘Sleep problems’ in IDD populations are by no
means equivalent issues and should not be treated so.
Estimating individual circadian functioning is there-
fore critical in order to guide appropriate treatment
choices, together with the timing of any treatment ad-
ministration (e.g. melatonin, bright light therapy) [55].
Employing actigraphy in clinical practice with MPS III
populations would aid assessment and enable inter-
ventions to be targeted to individual difficulties. It
would also provide a baseline of sleep and circadian
rhythm functioning in a condition involving progres-
sive developmental decline, which may allow for ef-
fective evaluation of new treatments targeting disease
progression [27].
Enhancing parental understanding of their child’s cir-
cadian rhythm and sleep disruption may inherently re-
lieve some of the associated anxiety and stress regarding
sleep; although the impact of caring for a child with
sleep difficulties is by no means dismissed. By providing
an explanation for the sleep problem, any negative per-
ceptions that parents may hold in relation to their child’s
sleep or parenting abilities could potentially be altered.
Using actigraphy would enable these individual sleep
patterns to be identified and explained to parents, allow-
ing for implementation of daytime and bedtime routines
that fit with the individual child’s circadian rhythm. Evi-
dence supports the use of behavioural intervention for
sleep problems in children with IDD [7, 56]; therefore,
there should be routine screening for sleep difficulties in
children with MPS III, comprehensive assessment of the
nature of sleep disturbance and implementation of sub-
sequent tailored interventions incorporating behavioural
strategies. Based on parent and clinician report, exogen-
ous melatonin has been suggested as the most effective
pharmacological treatment for sleep problems in MPS
III [31, 34]; however, its limited, short-term effects in
some cases may be explained by an increased disruption
of circadian rhythm functioning. Alternative treatments,
such as light therapy and pharmacological agents acting
upon the endogenous melatonin system, are considered
for the circadian rhythm disorder, Smith-Magenis syn-
drome [21, 57] and may be worth an investigation as
treatment options in MPS III.
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Conclusions
This study provides further evidence for the notion of an
impairment in circadian rhythm functioning in children
with MPS III. Further research is required to investigate
this difference longitudinally, across MPS III subtypes
and in relation to the circadian rhythm of endogenous
melatonin and cortisol systems. Given the high preva-
lence of sleep problems in MPS III and the negative im-
pact of childhood sleep disturbance on individual and
family functioning, these findings are particularly rele-
vant for clinical management of sleep in MPS III. It re-
mains imperative to attempt to ascertain the underlying
aetiology of sleep and circadian rhythm disturbance, in
order that appropriate behavioural and pharmacological
interventions can be targeted for the individual.
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